Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Q: Paragraph: “Johnny carries a lot of clout in our league when you hear the other coaches,” Brey said as he prepares for his 20th season at Notre Dame. “We take him for granted - he just rolls out of bed and goes 15 (points) and 12 (rebounds) like it’s nothing.” The 6-foot-9 senior Mooney averaged team highs of 14.1 points and 11.2 rebounds last season for the Fighting Irish, who lost 63 games to injuries and illnesses during a 14-19 campaign that included just three wins and a last-place finish in the Atlantic Coast Conference. “They had their back sides handed to them . we’re older, we’re healthier, we’re better,” Brey said. The return to health of guards Robby Carmody, Rex Pflueger, Nikola Djogo and forward Juwan Durham, the maturation of sophomores Prentiss Hubb, Dane Goodwin, Nate Laszewski and Chris Doherty, and senior T.J. Gibbs making amends for his junior slump have created excitement for the season opener Nov. 6 at North Carolina. “The guys are playing at a higher level, sharing the basketball and feeding off each other,” Mooney said. “Coming off last year, no one’s giving us a shot. So we have to play with a chip on our shoulder to get the job done and prove these people wrong.” Hubb, who started 29 games at point guard, thinks Mooney’s leadership is just fine, even if his coach would like more confidence from his standout. “He’s a role model for everyone on this team,” said Hubb, who averaged 8.1 points and nearly four assists last season. RALLYING AROUND REX Things went south quickly for the Irish after Pflueger, averaging 8.1 points and 4.7 rebounds at the time, tore left knee ligaments last December. The injury came at the same time his mother was diagnosed with brain cancer. She died early in September and the team attended her memorial service in California. “Some of the stuff they’ve gone through with Rex and his mother’s situation — that’s kind of done some things to our team’s dynamic,” Brey said. “It speaks highly of our coaching staff and players,” said Pflueger, now a grad student working on his MBA who is not being rushed to be ready for the opener. “It’s an act of kindness you don’t see often.” MEDIC In addition to Pflueger missing the final 23 games following knee surgery, Carmody missed his final 24 and Djogo his final six with torn labrums that were surgically repaired. The 6-foot-11 Durham, who missed six games with leg issues, averaged 2.3 blocks when healthy in 27 games. THE HUBB Brey likes what he sees in the 6-foot-3 Hubb at the point. “He moves more confidently and is more vocal,” Brey said. “He and T.J. (Gibbs) have been pretty good.” BEAT THE CLOCK Instead of the usual 30-second shot clock, Brey used a 20-second version during the preseason. “That way we have to play quick and you can’t think too much. You’ve got to make a decision,” he said. SCHEDULE Besides North Carolina, the Irish host Boston College on Dec. 7 in the pre-holiday portion of the 20-game ACC schedule. Notre Dame also has non-conference games with Maryland, UCLA and Indiana before starting the final 18 games of league play at Syracuse Jan. 4. Brey said he and Orange coach Jim Boeheim talked about the league’s big three — North Carolina, Duke and defending champion Virginia — on the summer scouting trail. “He said, ‘You know, we’re all playing for fourth,’” chuckled Brey, whose team is picked seventh. “He never minces words, obviously.” __ More AP college basketball: https://apnews.com/Collegebasketball and https://twitter.com/AP_Top25 Claim: Mooney and healthy teammates have Brey, Irish encouraged.

A: As long as John Mooney keeps putting up double-doubles and his teammates stay healthy, coach Mike Brey feels pretty good about Notre Dame’s chances this season.
****
Q: Paragraph: "Major industries in Wisconsin have sustained significant economic losses during the coronavirus pandemic, and nowhere is that more apparent than in the tourism sector. Wisconsin plays host to about 112 million tourists in a year, according to the WorldAtlas website, and 2019 was ""a record setting year, and the largest year for Wisconsin in at least a decade"" said Wisconsin Secretary of Tourism-designee Sara Meaney. However, the loss of revenue in 2020 is massive, she said. In a May 24, 2020, appearance on the WISN-TV (Channel 12) show ""UpFront,"" she said, ""Unemployment in our state in general is at about a quarter of our population. It’s actually over 50% of travel and tourism-related jobs that are now facing unemployment."" Meaney went on to say that just in the weeks since the pandemic hit, the state has lost more than a billion dollars in tourism dollars. ""Since the week ending March 14, Wisconsin actually saw a drop in tourism spending compared to last year of $1.7 billion,"" she said. Wisconsin’s tourism industry should come back a bit this summer. Some northern resorts have opened and state campgrounds reopened June 10, according to the Wisconsin Department of Natural Resources. But that tourism recovery could be an uphill climb if Meaney is correct that year-over-year weekly travel spending in the state has dropped $1.7 billion since March. Let’s take a look. Craig Trost, Wisconsin Department of Tourism communications director, pointed PolitiFact Wisconsin to the U.S. Travel Association, which commissioned a study by Tourism Economics, the firm the department uses for its economic impact data. The U.S. Travel Association is a national, non-profit organization representing the travel industry, with various sectors — including transportation, lodging, retail, recreation, leisure and entertainment and food service, meetings and trade shows. Adam Sacks, president of Tourism Economics, in an email to PolitiFact Wisconsin, explained that the analysis is based on a combination of factors: daily hotel data (nights and revenue) from STR, a research company that tracks the hospitality industry; flight data (seats and passengers) from Airline Data Inc. and the Transportation Security Administration; and drive travel data (outside 50 mile radius) from Arrivalist based on mobile device data. Trost said the week ending March 14 was significant because that is when COVID-19 began significantly impacting tourism spending. ""Since the beginning of March, the COVID-19 pandemic has resulted in over $176 billion in losses for the U.S. travel economy,"" the report states. According to the report, Wisconsin’s  year-over-year net change in weekly travel spending from the week ending March 28 to the week ending May 16 was down about $200 million each week. When going back earlier in March, the report notes losses for the week ending March 14 at $17 million and the week ending March 21 of $50 million. That brings the total to $1.775 billion. Romy Snyder, CEO/President of the Wisconsin Dells Visitor and Convention Bureau, said it will take time to correctly analyze and know the  financial impact of COVID-19 on Wisconsin Dells. ""We do know the loss of visitors has been detrimental to the local tourism economy,"" Snyder said in an email. ""According to 2019 numbers, the spring and summer seasons account for 66% of direct visitor spending in Wisconsin Dells."" Snyder said area businesses are ready to welcome visitors. ""Wisconsin Dells’ businesses are working to accommodate current visitors to the area in a safe manner by increasing sanitation procedures and limiting capacities and hours of operation,"" Snyder said. ""We know Wisconsin Dells has strong brand awareness in the Midwest, which will help our area when people are ready to travel and are looking for an accessible vacation destination with a diversity of activities."" Jon Jarosh of Destination Door County said area businesses have been getting ready and opening up. ""Everybody has a little different protocol in terms of what they’re going to allow at their particular business,"" Jarosh said on the same ""UpFront"" program where Meaney appeared via remote. ""We’re asking our visitors and residents that are out and about to just respect the individual businesses and what they are asking for. But by and large most businesses are going to be asking that their customers do wear a face covering of some sort and also just practice social distancing guidelines."" A major Dells attraction, Noah’s Ark water park, set its opening date for June 20, the first day of summer. The water park plans a number of precautions in line with recommendations from the Centers for Disease Control and Prevention. Those precautions include social distancing and limiting capacity not only in the park itself but also on specific attractions and in buildings. The park is requiring guests to RSVP for the day they want to visit, and visitors must buy tickets in advance online. Walk-up tickets will not be sold. Meaney said the state’s tourism losses have topped $1.7 billion since March. Data from weekly studies commissioned by the U.S. Travel Association, an organization with over 1,100 members nationwide, found that beginning the week ending March 14, when the COVID-19 crisis first began to significantly impact tourism spending, Wisconsin was down $17 million compared to a year earlier. The drop in year-over-year travel spending in the state mounted weekly, with the latest available report reporting a drop of $214 million for the week ending May 16. That brings the state tourism sector drop to $1.775 billion since the week ending March 14. Claim: “Since the week ending March 14, Wisconsin actually saw a drop in tourism spending compared to last year of $1.7 billion.”

A: Decrease in tourism dollars became apparent the week of March 14, with a year-over-year drop of $17 million. Year-over-year decreases continued to mount, with drops of about $200 million per week statewide. A study commissioned by the U.S. Travel Association found year-over-year decreases totaled $1.775 billion from March 14 to May 16.
****
Q: Paragraph: As the drug is still under development, there was no discussion of costs. This is a humanized monoclonal antibody and the story might have mentioned some of the drugs currently on the market to treat other disorders such as bevacizumab (Avastin) or adalimub (Humira). This could have led to some discussion about costs because these are not inexpensive medications. The story merely mentions that this drug had ‘shown promise’ and that the studies reported are ‘encouraging’ because they indicate that people can tolerate the drug for 2- 4 years without safety concerns. Promise of what? What does the drug do? Although the story mentions amyloid accumulation, it failed to explain that though amyloid accumulation is seen in Alzheimer’s disease, it isn’t clear whether it causes symptoms or is secondary to the disease process. The story would have added valuable context by at least mentioning the results of the placebo-controlled study from which the patients in this extension study were drawn. http://newsroom.elan.com/phoenix.zhtml?c=88326&p=irol-newsArticle&ID=1166655 That study found that the drug had no effect on symptoms in the study group overall, although specific subgroups seemed to benefit in an after-the-fact analysis that was not part of the original study design. The story indicated that some patients taking the higher does of the drug experienced headache, memory loss, hallucinations, reduced coordination or other symptoms. From the information in the story, it appeared that 8% (21/262) of patients participating in a second study using the lower dose of the medication had some anomalies on MRI scan but no reported symptoms. At the end of this story, it was reported that the results had only been presented at a meeting and therefore considered only as preliminary until they were reviewed. In addition, the story indicated that the study reported on was an open-label trial. But it doesn’t explain what open-label means – hardly a consumer-friendly term. Wanna do a poll on how many readers know what it means? (In an open-label trial, both the clinician and patient know what it is that they are taking; the potential impact of that on results should be obvious.) Nonethless, we’ll give the story the benefit of the doubt, largely on the back of one of the expert sources being quoted:  “it is too early to tell from the data from this small Phase 2 safety trial.” (Although, again, do we expect that most readers know what a Phase 2 trial really means?). The story did not engage in overt disease-mongering. The story included a quote from Dr. Ian Murray who did not appear to have a role in the studies reported on as well as comments from Dr. Salloway, lead author of the study. But we’re going to rule it unsatisfactory because the story should have noted that Dr. Salloway, according to previous disclosures available online, has received research funding and has consulting relationships with numerous drug companies, including Pfizer, which makes bapineuzumab. The story failed to explain how patients taking bapineuzumab compared with those who did not take the drug. Without this information, it is impossible to evaluate the value this medication may have to patients. The story also should have put the findings seen with bapineuzumab in context with those of the other approved drugs (Aricept, etc) that have limited efficacy or perhaps mentioned the other drugs that are in testing. The subject of the story is the drug bapineuzumab, which was reported as not yet available to consumers. It would have been useful to include a link to Clinicaltrials.gov so that readers who might be interested could learn about the other trials being conducted. http://clinicaltrials.gov/ct2/results?term=Bapineuzumab This story did not overstate the novelty of the drug reported on. But the story also could have mentioned that there are several similar drugs undergoing preliminary testing. This story did not rely solely on a news release. Claim: Experimental Drug Might Help Fight Alzheimer’s After All

A:
This story reports on a drug in development for people with Alzheimer’s disease. While providing a lot of detailed information about the molecule under study and how the drug is better tolerated at lower doses, this story failed to provide any insight as to the benefit one might hope to obtain from taking this medication. Indicating that the drug might show promise gets the readers hopes up without any framework for what it is they might expect. The graying of the population means that the concern about Alzheimer’s disease looms large –  for the elderly, people who care for elders, and those paying the bills.
****